^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ABL103
i
Other names: ABL103, ABL 103, TRIA002, ABL-103, TRIA-002, TRIA 002
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
ABL Bio, Handok
Drug class:
CD137 agonist, B7-H4 inhibitor
Related drugs:
2ms
ABL103-1001: A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=96, Recruiting, ABL Bio, Inc. | Trial primary completion date: Jun 2025 --> Dec 2025
Trial primary completion date
|
ABL103
3ms
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1/2, N=65, Recruiting, ABL Bio, Inc.
New P1/2 trial
|
Keytruda (pembrolizumab) • ABL103
10ms
ABL103-1001: A Study with ABL103 in Subjects with Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=96, Recruiting, ABL Bio, Inc. | Trial primary completion date: Nov 2024 --> Jun 2025
Trial primary completion date
|
ABL103
2years
A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=96, Recruiting, ABL Bio, Inc.
New P1 trial • Metastases
|
ABL103
over3years
ABL103, A novel T-cell engaging bispecific antibody, exhibits potent in vitro and vivo antitumor activity and low toxicity via B7-H4 dependent 4-1BB activation in tumor microenvironment (AACR 2022)
Overall, ABL103 has a strong in vitro and vivo anti-tumor activity and good safety profile via B7-H4-dependent 4-1BB activation. This strongly suggests ABL103 is a promising therapeutic agent potentially benefitting patients with B7-H4 overexpression.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • CD4 (CD4 Molecule)
|
CD8 expression • VTCN1 underexpression
|
ABL103
Share via
